Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 4

Jazz Pharmaceuticals plc

JAZZNASDAQEQUITYCurrent

SEC Filing

Filed Sep 10, 2026Accepted Sep 10, 2026, 4:28 PM EDTCIK 1232524Accession 0001989533-26-000019
Share

Company context

global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Current securities

Recent company filings

  1. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 23, 2026
  2. Regulation FD DisclosureSep 15, 2026
  3. 144 filingSep 10, 2026
  4. 144 filingSep 8, 2026
  5. 144 filingSep 8, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗